Céline Calbrix

Kinetics, prognostic and predictive values of <i>ESR1</i> circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor

Florian Clatot, Anne Perdrix, Laetitia Augusto et al. · Oncotarget · 2016 · 98 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Impact of Taxanes, Endocrine Therapy, and Deleterious Germline BRCA Mutations on Anti-müllerian Hormone Levels in Early Breast Cancer Patients Treated With Anthracycline- and Cyclophosphamide-Based Chemotherapy

Matteo Lambertini, Nathalie Olympios, Justine Lequesne et al. · Frontiers in Oncology · 2019 · 65 citations · Full text

Medicine, Oncology, Pharmacology +17

Risk of early progression according to circulating ESR1 mutation, CA-15.3 and cfDNA increases under first-line anti-aromatase treatment in metastatic breast cancer

Florian Clatot, Anne Perdrix, Ludivine Beaussire et al. · Breast Cancer Research · 2020 · 43 citations · Full text

Medicine, Endocrinology, Oncology +17

Molecular basis of agonist docking in a human<scp>GPR</scp>103 homology model by site‐directed mutagenesis and structure–activity relationship studies

Cédric Neveu, Fabienne Dulin, Benjamin Lefranc et al. · British Journal of Pharmacology · 2014 · 13 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Circulating PIK3CA mutation detection at diagnosis in non-metastatic inflammatory breast cancer patients

Violette Allouchery, Anne Perdrix, Céline Calbrix et al. · Scientific Reports · 2021 · 11 citations · Full text

Medicine, Molecular Medicine, Oncology +17